Jazz Pharmaceuticals (JAZZ) 136.15 $JAZZ
How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
Jazz Pharmaceuticals Has Returned 11.5% Since SmarTrend Recommendation (JAZZ)
Comtex SmarTrend(R) - Mon Apr 14, 11:13AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.30. In approximately 1 month, Jazz Pharmaceuticals has returned 11.51% as of today's recent price of $132.99.
Insider Trading Alert - JAZZ, GDOT And MDSO Traded By Insiders
at The Street - Fri Apr 11, 9:15AM CDT
Stocks with insider trader activity include JAZZ, GDOT and MDSO
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Acquisitions, Trial Study Results, Drug Trend Reports, Conference Call Schedules, and Product Launches - Analyst Notes on Mallinckrodt, Amgen, Express Scripts, CR Bard, and Jazz
PR Newswire - Thu Apr 10, 10:36AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
Commit To Purchase Jazz Pharmaceuticals At $105, Earn 11.2% Annualized Using Options
at The Street - Mon Apr 07, 10:44AM CDT
Investors eyeing a purchase of Jazz Pharmaceuticals shares, but tentative about paying the going market price of $127.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Jazz Pharmaceuticals Shares Down 14.3% Since SmarTrend's Sell Call (JAZZ)
Comtex SmarTrend(R) - Mon Apr 07, 9:57AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.30. In approximately 1 month, Jazz Pharmaceuticals has returned 14.26% as of today's recent price of $128.87.
3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 1:10PM CDT
Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable failure. ...
After Yesterday's Decline of 3.56%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 03, 4:39PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $132.56 to a high of $141.23. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $134.55 on volume of 912,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Buying Slow Moves Can Cost You In Lost Opportunities
at Investor's Business Daily - Wed Apr 02, 5:11PM CDT
Putting slower-moving stocks in your portfolio is a lot like hiring lazy workers who don't do squat for your business. You're not going to make much progress with either, and both will end up costing you in lost opportunities. In investing, the big...
Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?
Brian Nichols, The Motley Fool - Motley Fool - Wed Apr 02, 4:16PM CDT
Back in January, the Daily Mail ran a story suggesting that pharmaceutical companies Eli Lilly and GlaxoSmithKline had shown interest in Ariad Pharmaceuticals . According to another recent article by the same publication, however, Jazz...
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Community Health, and United Technologies
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Community Health Systems, Inc. (NYSE: CYH), and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Markets Are Rigged - Analyst Blog
Kevin Cook - Zacks Investment Research - Tue Apr 01, 3:37PM CDT
Can we learn to thrive in the HFT/algo world?
Markets Are Rigged - Real Time Insight
Kevin Cook - Zacks Investment Research - Tue Apr 01, 9:53AM CDT
Can we learn to thrive in the HFT/algo world?
Biotechs Giving Uncle Sam the Shaft
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 5:08PM CDT
As they say in real estate: location, location, location. Biotechs have been acquiring companies in large part for their address. Specifically, they're buying so they can move to places like Ireland, where taxes are substantially lower than in the...
Downtrend Call Working As Jazz Pharmaceuticals Stock Falls 8.7% (JAZZ)
Comtex SmarTrend(R) - Mon Mar 31, 9:30AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.29. In approximately 4 weeks, Jazz Pharmaceuticals has returned 8.66% as of today's recent price of $137.28.
How Are Orphan Drugmakers Faring in the Great Biotech Downturn?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
There is little debate that we are now in the throes of a general market correction. And because health-care and biotech stocks were the best performers over the past few years, they are being hit particularly hard in this downturn. That said, we...
Jazz Pharmaceuticals Has Returned 11.5% Since SmarTrend Recommendation (JAZZ)
Comtex SmarTrend(R) - Mon Apr 14, 11:13AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.30. In approximately 1 month, Jazz Pharmaceuticals has returned 11.51% as of today's recent price of $132.99.
Insider Trading Alert - JAZZ, GDOT And MDSO Traded By Insiders
at The Street - Fri Apr 11, 9:15AM CDT
Stocks with insider trader activity include JAZZ, GDOT and MDSO
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Acquisitions, Trial Study Results, Drug Trend Reports, Conference Call Schedules, and Product Launches - Analyst Notes on Mallinckrodt, Amgen, Express Scripts, CR Bard, and Jazz
PR Newswire - Thu Apr 10, 10:36AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
Commit To Purchase Jazz Pharmaceuticals At $105, Earn 11.2% Annualized Using Options
at The Street - Mon Apr 07, 10:44AM CDT
Investors eyeing a purchase of Jazz Pharmaceuticals shares, but tentative about paying the going market price of $127.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Jazz Pharmaceuticals Shares Down 14.3% Since SmarTrend's Sell Call (JAZZ)
Comtex SmarTrend(R) - Mon Apr 07, 9:57AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.30. In approximately 1 month, Jazz Pharmaceuticals has returned 14.26% as of today's recent price of $128.87.
3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 1:10PM CDT
Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable failure. ...
After Yesterday's Decline of 3.56%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 03, 4:39PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $132.56 to a high of $141.23. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $134.55 on volume of 912,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Buying Slow Moves Can Cost You In Lost Opportunities
at Investor's Business Daily - Wed Apr 02, 5:11PM CDT
Putting slower-moving stocks in your portfolio is a lot like hiring lazy workers who don't do squat for your business. You're not going to make much progress with either, and both will end up costing you in lost opportunities. In investing, the big...
Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?
Brian Nichols, The Motley Fool - Motley Fool - Wed Apr 02, 4:16PM CDT
Back in January, the Daily Mail ran a story suggesting that pharmaceutical companies Eli Lilly and GlaxoSmithKline had shown interest in Ariad Pharmaceuticals . According to another recent article by the same publication, however, Jazz...
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Community Health, and United Technologies
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Community Health Systems, Inc. (NYSE: CYH), and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Markets Are Rigged - Analyst Blog
Kevin Cook - Zacks Investment Research - Tue Apr 01, 3:37PM CDT
Can we learn to thrive in the HFT/algo world?
Markets Are Rigged - Real Time Insight
Kevin Cook - Zacks Investment Research - Tue Apr 01, 9:53AM CDT
Can we learn to thrive in the HFT/algo world?
Biotechs Giving Uncle Sam the Shaft
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 5:08PM CDT
As they say in real estate: location, location, location. Biotechs have been acquiring companies in large part for their address. Specifically, they're buying so they can move to places like Ireland, where taxes are substantially lower than in the...
Downtrend Call Working As Jazz Pharmaceuticals Stock Falls 8.7% (JAZZ)
Comtex SmarTrend(R) - Mon Mar 31, 9:30AM CDT
SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.29. In approximately 4 weeks, Jazz Pharmaceuticals has returned 8.66% as of today's recent price of $137.28.
